The value of observational registry studies for the next infectious disease emergency

Jonathon W. Senefeld; Peter Marks; Arturo Casadevall; Michael J. Joyner

doi:10.1128/mbio.02565-23

mBio (Dec 2023)

The value of observational registry studies for the next infectious disease emergency

Jonathon W. Senefeld,
Peter Marks,
Arturo Casadevall,
Michael J. Joyner

Affiliations

Jonathon W. Senefeld: Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
Peter Marks: Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
Arturo Casadevall: Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Michael J. Joyner: Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA

DOI: https://doi.org/10.1128/mbio.02565-23
Journal volume & issue: Vol. 14, no. 6

Abstract

Read online

ABSTRACTDuring infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.

Published in mBio

ISSN: 2161-2129 (Print); 2150-7511 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/mbio

About the journal

Abstract

Keywords